Disclaimer: Anything that is express in the following conversation are Michael's views and not necessarily those of Roche / Genentech. Synopsis: Michael Rosenblatt is the Vice President of Clinical Operations at Roche, leading their organization to reduce hierarchy, embrace agility, and increase engagement. Michael has spent the last 11 years between regulatory and clinical operations in late stage development at Roche/Genentech and is currently leading its GI indications from an operational standpoint. He provides his perspective on the clinical operations landscape now and what’s changed over the last five-seven years. He shares the technology he’s excited by that has the potential to transform R&D and clinical operations. He discusses his role at Roche and some of the transformation underway bringing more treatments and better outcomes to patients everywhere! Biography: Michael Rosenblatt is a Vice President in Roche’s late stage clinical operations group (PDG). In this role he is responsible for registrational clinical trials for Roche’s Gastroenterology and Hepatology portfolio. He also acts as a mentor and coach for the countries in Roche’s Asian operational footprint. In this role he helps to ensure that Roche is taking full advantage of the talent and capabilities in that region. Michael is also part of the team leading the transformation of Roche’s Clinical Operations function, moving from a siloed hierarchical structure to a flatter, more agile organization. In this transformation Roche has helped rethink Clinical Operations, enabling talent flow across disease areas and cross-functional projects and empowering teams to make decisions closest to the work and takes. This work is unleashing significant efficiencies and helping Roche reach its goal of bringing new medicines to patients faster. In earlier roles at Roche, Michael oversaw key infrastructure for both the Clinical Operations and Regulatory groups at Roche and helped pioneer early eTMF processes and technology. Prior to joining Roche, Michael was a consultant in IBM’s life sciences consulting and business process management practices working with multiple pharmaceutical companies to introduce processes and technology designed to streamline and simplify work across finance, commercial, regulatory and other business units. He has also held numerous consulting, sales, marketing, and operational roles for several other US-based enterprises. Michael is an avid runner and swimmer. He resides near San Francisco, CA with his wife and two boys.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related